Loading
Latest filing published 26 May 2022 for Antares Pharma, INC., €724k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Leonard S. Jacob (board member) discloses dealings in Antares Pharma, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 10 June 2021 and the latest from 24 May 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 26 May 2022, the filings show a transaction worth €724k in Antares Pharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations